Thyroid Eye Disease (TED)
21
7
10
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 21 trials
100.0%
+13.4% vs benchmark
48%
10 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (21)
MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
A Clinical Study of Cizutamig in Thyroid Eye Disease
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
Treatment of Chronic Thyroid Eye Disease With MHB018A
Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study
Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease
Psychological Burden of Thyroid Eye Disease
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease